Cargando…

EGFR mutation is positively correlated with C-Met protein expression: a study of 446 resected lung adenocarcinoma

BACKGROUND: Epidermal growth factor receptor (EGFR) mutation and mesenchymal-epithelial transition factor (C-Met) amplification are known factors for primary resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in advanced primary lung adenocarcinoma. However, little is known about the relation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lei, Huizi, Liu, Li, Wei, Jiacong, Liu, Yutao, Ling, Yun, Wang, Xin, Guo, Lei, Li, Weihua, Ying, Jianming, Yang, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797278/ https://www.ncbi.nlm.nih.gov/pubmed/35116255 http://dx.doi.org/10.21037/tcr-20-2202

Ejemplares similares

MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition
por: Ortiz-Zapater, Elena, et al.
Publicado: (2017)

Metastatic adenocarcinoma to the breast from the lung simulates primary breast carcinoma—a clinicopathologic study
por: Wang, Xin, et al.
Publicado: (2021)

PM446. The relationship between MMN and COMT Val108/158Met genotype in schizophrenia
por: Horikoshi, Sho, et al.
Publicado: (2016)

MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma
por: Zhang, Jing, et al.
Publicado: (2016)

Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma
por: Nie, Yunqiang, et al.
Publicado: (2017)

The Relationship between TTF-1 Expression and EGFR Mutations in Lung Adenocarcinomas
por: Shanzhi, Wan, et al.
Publicado: (2014)

Emergence of Resistance to MTI-101 Selects for a MET Genotype and Phenotype in EGFR Driven PC-9 and PTEN Deleted H446 Lung Cancer Cell Lines
por: Jones, Clark, et al.
Publicado: (2022)

Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases
por: Shi, Liang, et al.
Publicado: (2021)

Correlation of circulating tumor DNA EGFR mutation levels with clinical outcomes in patients with advanced lung adenocarcinoma
por: Liu, Xiang-Liang, et al.
Publicado: (2021)

An animal model for Pierpont syndrome: a mouse bearing the Tbl1xr1(Y446C/Y446C) mutation
por: Hu, Yalan, et al.
Publicado: (2022)

Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung Adenocarcinoma
por: Ito, Masaoki, et al.
Publicado: (2020)

Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation–Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma
por: Kim, Chi Hong, et al.
Publicado: (2015)

A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib
por: Chen, Yan, et al.
Publicado: (2022)

MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation
por: Noro, Rintaro, et al.
Publicado: (2015)

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase
por: Dong, Jiang-Kai, et al.
Publicado: (2018)

Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation
por: Bruno, Rossella, et al.
Publicado: (2021)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

CT features associated with EGFR mutations and ALK positivity in patients with multiple primary lung adenocarcinomas
por: Han, Xiaoyu, et al.
Publicado: (2020)

Silencing of LOC389641 impairs cell proliferation and induces autophagy via EGFR/MET signaling in lung adenocarcinoma
por: Xiao, Lei, et al.
Publicado: (2020)

Effects of Ethnicity on Outcomes of Patients With EGFR Mutation–Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection
por: Sung, Mike R., et al.
Publicado: (2021)

Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma
por: Xiao, Gang, et al.
Publicado: (2023)

Effectiveness of crizotinib in a patient with mesenchymal-epithelial transition overexpression/fluorescence in situ hybridization-negative/next-generation sequencing-negative advanced lung adenocarcinoma: a case report
por: Song, Peng, et al.
Publicado: (2019)

Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2020)

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum
por: Dong, Jiang-Kai, et al.
Publicado: (2021)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation
por: Cai, Boning, et al.
Publicado: (2021)

Correlation between high-resolution computed tomography lung nodule characteristics and EGFR mutation in lung adenocarcinomas
por: Nie, Yunqiang, et al.
Publicado: (2019)

Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?
por: Kanemura, Hiroaki, et al.
Publicado: (2020)

Value of CT features for predicting EGFR mutations and ALK positivity in patients with lung adenocarcinoma
por: Han, Xiaoyu, et al.
Publicado: (2021)

The clinicopathological and molecular characteristics of resected EGFR‐mutant lung adenocarcinoma
por: Zhou, Wensheng, et al.
Publicado: (2022)

UP446, analgesic and anti-inflammatory botanical composition
por: Yimam, Mesfin, et al.
Publicado: (2013)

EGFR gene-mutation status correlated with therapeutic decision making in lung adenocarcinoma
por: Ren, Yaoyao, et al.
Publicado: (2015)

Outcomes of salvage lung resections in advanced EGFR ‐mutant lung adenocarcinomas under EGFR TKIs
por: Chen, Ying‐Yuan, et al.
Publicado: (2021)

Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients
por: Sun, Yan, et al.
Publicado: (2014)

Adjuvant EGFR-TKI therapy in resected EGFR-mutation positive non-small cell lung cancer: A real-world study
por: Liu, Jun-Feng, et al.
Publicado: (2023)

Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma
por: Liu, Yang, et al.
Publicado: (2019)

The Correlation between EGFR Mutation Status and DNA Content of Lung Adenocarcinoma Cells in Pleural Effusion
por: Du, Yun, et al.
Publicado: (2020)

Comparison of Clinicopathological Features and Prognosis between ALK Rearrangements and EGFR Mutations in Surgically Resected Early-stage Lung Adenocarcinoma
por: Li, Pupu, et al.
Publicado: (2019)

Prognostic implication of EGFR gene mutations and histological classification in patients with resected stage I lung adenocarcinoma
por: Lin, Chun-Yu, et al.
Publicado: (2017)

The prognostic implications of EGFR mutation and ALK rearrangement for the long‐term outcomes of patients with resected lung adenocarcinomas
por: Kim, Hyungjin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_q75v4supe0hpkpquqb1okcqeae